Hydrocortisone Mitigates Alzheimer’s-Related Cognitive Decline through Modulating Oxidative Stress and Neuroinflammation
Cells · 25.09.2023 · 12 (19) · 2348
DOI: 10.3390/cells12192348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 25.09.2023. Verfasst von Jinran Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, Chin…. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leading Technology Foundation Research Project of Jiangsu Province, Nature Science Foundation of Jiangsu Province, Postdoctoral Excellence Program of Jiangsu Province, Sanming Project of Medicine in Shenzhen.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD), an age-related degenerative disorder, is characterized by β-amyloid deposition, abnormal phosphorylation of tau proteins, synaptic dysfunction, neuroinflammation, and oxidative stress. Despite extensive research, there are no medications or therapeutic interventions to completely treat and reverse AD. Herein, we explore the potential of hydrocortisone (HC), a natural and endogenous glucocorticoid known to have potent anti-inflammatory properties, in an Aβ1–42-induced AD mouse model. Our investigation highlights the beneficial effects of HC administration on cognitive impairment, synaptic function enhancement, and neuronal protection in Aβ1–42-induced AD mice. Notably, HC treatment effectively suppresses the hyperactivation of microglia and astrocytes, leading to a reduction in proinflammatory factors and alleviation of neuroinflammation. Furthermore, HC intervention demonstrates the capacity to mitigate the generation of ROS and oxidative stress. These compelling findings underscore the potential therapeutic application of HC in AD and present promising opportunities for its utilization in AD prevention and treatment. The implications drawn from our findings indicate that hydrocortisone holds promise as a viable candidate for adjunctive use with other anti-AD drugs for the clinical management of patients presenting with moderate to severe AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.
- School of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, UK.
ORCID-Profile: Zheying Zhu
Förderung
- Leading Technology Foundation Research Project of Jiangsu Province
- Nature Science Foundation of Jiangsu Province
- Postdoctoral Excellence Program of Jiangsu Province, Sanming Project of Medicine in Shenzhen
- National Natural Science Foundation of China
- China Pharmaceutical University
Zitieren
APA
Li, J., Chen, L., Liu, S., Sun, Y., Zhen, L., Zhu, Z., Wang, G., & Li, X. (2023). Hydrocortisone Mitigates Alzheimer’s-Related Cognitive Decline through Modulating Oxidative Stress and Neuroinflammation. Cells, 12(19), 2348. https://doi.org/10.3390/cells12192348
Vancouver
Li J, Chen L, Liu S, Sun Y, Zhen L, Zhu Z, et al. Hydrocortisone Mitigates Alzheimer’s-Related Cognitive Decline through Modulating Oxidative Stress and Neuroinflammation. Cells. 2023;12(19):2348. doi:10.3390/cells12192348
BibTeX
@article{Li2023,
author = {Li, Jinran and Chen, Long and Liu, Sai and Sun, Yuan and Zhen, Le and Zhu, Zheying and Wang, Guangji and Li, Xinuo},
title = {Hydrocortisone Mitigates Alzheimer’s-Related Cognitive Decline through Modulating Oxidative Stress and Neuroinflammation},
journal = {Cells},
year = {2023},
volume = {12},
number = {19},
pages = {2348},
doi = {10.3390/cells12192348}
}
EUVIMED